Tracking CMT with biomarkers over time
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study is looking for people with Charcot-Marie-Tooth disease (a nerve condition) and healthy volunteers to track long-term changes in the body. Researchers want to see if certain biomarkers (measurable signs) can help predict how CMT progresses over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- Either you have a confirmed CMT diagnosis (with genetic testing) or you are a healthy person without CMT.
- You must be able to complete the study's physical tests and measurements at the start.
- You cannot be pregnant or breastfeeding.
- You should not have any other major neurological or psychiatric conditions (like epilepsy, stroke, or depression) that could affect the study.
- You should not have a serious internal disease (like severe heart or lung problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for new markers of early Charcot-Marie-Tooth 1A (CMT1A) disease using blood tests and special MRI scans. It aims to help understand how the disease progresses and may lead to better treatments.
This study examines how autonomic nerves (the nerves that control automatic body functions like heart rate and blood pressure) are affected in people with CMT (Charcot-Marie-Tooth disease), a genetic nerve disorder. Understanding this may help improve treatment and quality of life for CMT patients.
This study examines tremor (involuntary shaking) in people with Charcot-Marie-Tooth disease, a genetic nerve condition that affects the legs and feet. Researchers will compare people with CMT who have tremor to healthy volunteers to better understand this symptom.
This study looks at how nerves work and their structure in people with Charcot-Marie-Tooth disease, CIDP, or anti-MAG neuropathy. It may help doctors better understand these conditions.
This study follows people who have Charcot-Marie-Tooth disease (CMT) and compares them with people without nerve disease. The goal is to better understand different CMT types and how symptoms and nerve test results change over time.
This trial looks for new markers of Charcot-Marie-Tooth 1A (CMT1A) early in the disease. Researchers hope to find signs that can help diagnose and track the disease better, which could lead to better treatments in the future.
Hear when a new CMT1A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.